Analysts Set Aemetis, Inc. (NASDAQ:AMTX) Price Target at $12.95

Aemetis, Inc. (NASDAQ:AMTX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the five brokerages that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $12.95.

A number of equities research analysts have recently issued reports on the company. Truist Financial restated a "hold" rating and set a $3.50 price objective (down previously from $4.00) on shares of Aemetis in a report on Wednesday, July 31st. HC Wainwright reiterated a "buy" rating and set a $28.00 price target on shares of Aemetis in a report on Friday. Ascendiant Capital Markets cut their price target on shares of Aemetis from $20.00 to $19.00 and set a "buy" rating on the stock in a research report on Tuesday, September 3rd. StockNews.com upgraded Aemetis to a "sell" rating in a report on Wednesday, July 31st. Finally, UBS Group dropped their price objective on Aemetis from $8.25 to $7.75 and set a "buy" rating on the stock in a research note on Monday, August 19th.

Institutional Investors Weigh In On Aemetis

A number of large investors have recently added to or reduced their stakes in the company. FMR LLC increased its holdings in shares of Aemetis by 68.2% in the third quarter. FMR LLC now owns 22,531 shares of the specialty chemicals company's stock worth $52,000 after buying an additional 9,137 shares during the period. SG Americas Securities LLC bought a new position in Aemetis in the 1st quarter worth about $60,000. Hutchinson Capital Management CA bought a new position in Aemetis in the 2nd quarter valued at approximately $70,000. State Board of Administration of Florida Retirement System purchased a new stake in shares of Aemetis during the 1st quarter valued at about $84,000. Finally, Barclays PLC boosted its stake in shares of Aemetis by 274.6% in the 3rd quarter. Barclays PLC now owns 47,496 shares of the specialty chemicals company's stock worth $109,000 after buying an additional 34,816 shares during the last quarter. Hedge funds and other institutional investors own 27.02% of the company's stock.

Aemetis Stock Performance

NASDAQ:AMTX traded down $0.24 on Friday, reaching $3.83. The company's stock had a trading volume of 713,435 shares, compared to its average volume of 840,780. The firm has a market cap of $190.50 million, a PE ratio of -1.69 and a beta of 1.23. Aemetis has a 1-year low of $2.10 and a 1-year high of $7.03. The business's 50-day moving average price is $2.80 and its two-hundred day moving average price is $3.05.

Aemetis (NASDAQ:AMTX - Get Free Report) last released its earnings results on Tuesday, November 12th. The specialty chemicals company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.09. The company had revenue of $81.44 million for the quarter, compared to the consensus estimate of $77.79 million. During the same quarter in the previous year, the company posted ($0.59) EPS. As a group, sell-side analysts expect that Aemetis will post -2.1 EPS for the current year.

About Aemetis

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.